Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense.

Public health assessment of potential biological terrorism agents. Emerg Infect Dis (2002) 8.49

Emergency response to a smallpox attack: the case for mass vaccination. Proc Natl Acad Sci U S A (2002) 7.78

Real-time PCR in clinical microbiology: applications for routine laboratory testing. Clin Microbiol Rev (2006) 6.03

Modeling potential responses to smallpox as a bioterrorist weapon. Emerg Infect Dis (2001) 3.39

Syndromic surveillance and bioterrorism-related epidemics. Emerg Infect Dis (2003) 3.00

Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox. Proc Natl Acad Sci U S A (2004) 2.36

Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice. J Virol (2005) 2.18

Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus. J Virol (2005) 2.11

Social contact networks and disease eradicability under voluntary vaccination. PLoS Comput Biol (2009) 1.96

Ring vaccination and smallpox control. Emerg Infect Dis (2004) 1.88

The host response to smallpox: analysis of the gene expression program in peripheral blood cells in a nonhuman primate model. Proc Natl Acad Sci U S A (2004) 1.85

Redundancy and plasticity of neutralizing antibody responses are cornerstone attributes of the human immune response to the smallpox vaccine. J Virol (2008) 1.77

Smallpox and pan-orthopox virus detection by real-time 3'-minor groove binder TaqMan assays on the roche LightCycler and the Cepheid smart Cycler platforms. J Clin Microbiol (2004) 1.77

Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals. Vaccine (2006) 1.71

Edward Jenner and the history of smallpox and vaccination. Proc (Bayl Univ Med Cent) (2005) 1.65

Detection of smallpox virus DNA by LightCycler PCR. J Clin Microbiol (2002) 1.62

Surface protein IsdC and Sortase B are required for heme-iron scavenging of Bacillus anthracis. J Bacteriol (2006) 1.59

Does smallpox still pose a threat? CMAJ (2001) 1.53

Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. Antimicrob Agents Chemother (2009) 1.52

Passive antibody administration (immediate immunity) as a specific defense against biological weapons. Emerg Infect Dis (2002) 1.51

Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction. J Clin Invest (2005) 1.50

Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate. Antimicrob Agents Chemother (2005) 1.48

Poxvirus Bioinformatics Resource Center: a comprehensive Poxviridae informational and analytical resource. Nucleic Acids Res (2005) 1.47

Enhanced drop-in syndromic surveillance in New York City following September 11, 2001. J Urban Health (2003) 1.45

Poxviruses as possible vectors for horizontal transfer of retroposons from reptiles to mammals. Proc Natl Acad Sci U S A (2007) 1.44

Gender effects on humoral immune responses to smallpox vaccine. Vaccine (2009) 1.39

Obligatory requirement for antibody in recovery from a primary poxvirus infection. J Virol (2006) 1.36

Persistence of category A select agents in the environment. Appl Environ Microbiol (2007) 1.35

Antivaccinia activities of acyclic nucleoside phosphonate derivatives in epithelial cells and organotypic cultures. Antimicrob Agents Chemother (2002) 1.31

Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus. Proc Natl Acad Sci U S A (2008) 1.31

Detection of orthopoxvirus DNA by real-time PCR and identification of variola virus DNA by melting analysis. J Clin Microbiol (2004) 1.30

Biological warfare and bioterrorism: a historical review. Proc (Bayl Univ Med Cent) (2004) 1.26

Comparative analysis of monkeypox virus infection of cynomolgus macaques by the intravenous or intrabronchial inoculation route. J Virol (2010) 1.25

The 1.51-Angstrom structure of the poxvirus L1 protein, a target of potent neutralizing antibodies. Proc Natl Acad Sci U S A (2005) 1.24

Risks of serious complications and death from smallpox vaccination: a systematic review of the United States experience, 1963-1968. BMC Public Health (2003) 1.24

Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. Antimicrob Agents Chemother (2008) 1.24

Genome-wide association study of antibody response to smallpox vaccine. Vaccine (2012) 1.23

Biological warfare and bioterrorism. BMJ (2002) 1.23

Smallpox vaccines: targets of protective immunity. Immunol Rev (2011) 1.21

Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8. Proc Natl Acad Sci U S A (2005) 1.13

Immunity from smallpox vaccine persists for decades: a longitudinal study. Am J Med (2008) 1.11

Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara. J Virol (2002) 1.11

A Canadian national survey of attitudes and knowledge regarding preventive vaccines. J Immune Based Ther Vaccines (2003) 1.11

A simulation analysis to characterize the dynamics of vaccinating behaviour on contact networks. BMC Infect Dis (2009) 1.10

Global health security and the International Health Regulations. BMC Public Health (2010) 1.07

Serine peptide phosphoester prodrugs of cyclic cidofovir: synthesis, transport, and antiviral activity. Mol Pharm (2008) 1.06

Capsule anchoring in Bacillus anthracis occurs by a transpeptidation reaction that is inhibited by capsidin. Mol Microbiol (2008) 1.06

Smallpox vaccine: the good, the bad, and the ugly. Clin Med Res (2003) 1.05

Endemic, notifiable bioterrorism-related diseases, United States, 1992-1999. Emerg Infect Dis (2003) 1.05

Smallpox still poses a threat. CMAJ (2002) 1.04

Inactivation of poxviruses by upper-room UVC light in a simulated hospital room environment. PLoS One (2008) 1.04

Statistical approach to estimate vaccinia-specific neutralizing antibody titers using a high-throughput assay. Clin Vaccine Immunol (2009) 1.04

Logistics of community smallpox control through contact tracing and ring vaccination: a stochastic network model. BMC Public Health (2004) 1.03

Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient mice. Proc Natl Acad Sci U S A (2009) 1.03

Combination therapy of vaccinia virus infection with human anti-H3 and anti-B5 monoclonal antibodies in a small animal model. Antivir Ther (2010) 1.02

Characterisation of the substrate specificity of homogeneous vaccinia virus uracil-DNA glycosylase. Nucleic Acids Res (2003) 1.01

Protection against vaccinia virus challenge by CD8 memory T cells resolved by molecular mimicry. J Virol (2006) 1.01

Structural basis for the binding of the neutralizing antibody, 7D11, to the poxvirus L1 protein. Virology (2007) 1.00

Antibody responses to vaccinia membrane proteins after smallpox vaccination. J Infect Dis (2007) 0.99

Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors. Expert Rev Vaccines (2011) 0.98

What was the primary mode of smallpox transmission? Implications for biodefense. Front Cell Infect Microbiol (2012) 0.96

Transcriptomic profiles of high and low antibody responders to smallpox vaccine. Genes Immun (2013) 0.94

Characterization of UVC light sensitivity of vaccinia virus. Appl Environ Microbiol (2007) 0.93

CD8 T cells are essential for recovery from a respiratory vaccinia virus infection. J Immunol (2012) 0.93

Progressive vaccinia: case description and laboratory-guided therapy with vaccinia immune globulin, ST-246, and CMX001. J Infect Dis (2012) 0.93

Diverse recognition of conserved orthopoxvirus CD8+ T cell epitopes in vaccinated rhesus macaques. Vaccine (2009) 0.92

Rapid and high-throughput pan-Orthopoxvirus detection and identification using PCR and mass spectrometry. PLoS One (2009) 0.92

Potent neutralization of vaccinia virus by divergent murine antibodies targeting a common site of vulnerability in L1 protein. J Virol (2014) 0.89

Vaccinia virus infection of mature dendritic cells results in activation of virus-specific naïve CD8+ T cells: a potential mechanism for direct presentation. Virology (2006) 0.88

Extracting key information from historical data to quantify the transmission dynamics of smallpox. Theor Biol Med Model (2008) 0.88

Role for CCR5 in dissemination of vaccinia virus in vivo. J Virol (2008) 0.88

Engineering the vaccinia virus L1 protein for increased neutralizing antibody response after DNA immunization. Virol J (2009) 0.87

Inhalational monkeypox virus infection in cynomolgus macaques. Front Cell Infect Microbiol (2012) 0.87

5-(Dimethoxymethyl)-2'-deoxyuridine: a novel gem diether nucleoside with anti-orthopoxvirus activity. J Med Chem (2006) 0.87

Aerosolized cidofovir is retained in the respiratory tract and protects mice against intranasal cowpox virus challenge. Antimicrob Agents Chemother (2003) 0.87

Progression of pathogenic events in cynomolgus macaques infected with variola virus. PLoS One (2011) 0.87

Risks and benefits of preexposure and postexposure smallpox vaccination. Emerg Infect Dis (2003) 0.86

Vaccinia virus-specific CD8(+) T-cell responses target a group of epitopes without a strong immunodominance hierarchy in humans. Hum Immunol (2008) 0.86

A novel high-throughput vaccinia virus neutralization assay and preexisting immunity in populations from different geographic regions in China. PLoS One (2012) 0.86

Smallpox during pregnancy and maternal outcomes. Emerg Infect Dis (2006) 0.85

Persisting humoral antiviral immunity within the Japanese population after the discontinuation in 1976 of routine smallpox vaccinations. Clin Diagn Lab Immunol (2005) 0.85

The heterogeneity of human antibody responses to vaccinia virus revealed through use of focused protein arrays. Vaccine (2009) 0.85

Emerging illness and bioterrorism: implications for public health. J Urban Health (2001) 0.85

Coadministration of cidofovir and smallpox vaccine reduced vaccination side effects but interfered with vaccine-elicited immune responses and immunity to monkeypox. J Virol (2008) 0.84

Smallpox and biological warfare: a disease revisited. Proc (Bayl Univ Med Cent) (2005) 0.84

Should the US and Russia destroy their stocks of smallpox virus? BMJ (2007) 0.84

Uncertain benefit: the public policy of approving smallpox vaccine research. Am J Public Health (2004) 0.83

Traditional smallpox vaccination with reduced risk of inadvertent contact spread by administration of povidone iodine ointment. Vaccine (2007) 0.83

The structure of G4, the poxvirus disulfide oxidoreductase essential for virus maturation and infectivity. J Virol (2006) 0.83

Synthesis and early development of hexadecyloxypropylcidofovir: an oral antipoxvirus nucleoside phosphonate. Viruses (2010) 0.83

Development of the small-molecule antiviral ST-246 as a smallpox therapeutic. Future Virol (2011) 0.82

CD4+ T cells provide intermolecular help to generate robust antibody responses in vaccinia virus-vaccinated humans. J Immunol (2013) 0.82

Unusual features of vaccinia virus extracellular virion form neutralization resistance revealed in human antibody responses to the smallpox vaccine. J Virol (2012) 0.82

Educating health professionals to respond to bioterrorism. Public Health Rep (2005) 0.81

The identification of HLA class II-restricted T cell epitopes to vaccinia virus membrane proteins. Virology (2010) 0.81

Contacting passengers after exposure to measles on an international flight: Implications for responding to new disease threats and bioterrorism. Public Health Rep (2004) 0.81

Use of internally controlled real-time genome amplification for detection of variola virus and other orthopoxviruses infecting humans. J Clin Microbiol (2006) 0.81

Real-time PCR assay for detection of a new simulant for poxvirus biothreat agents. Appl Environ Microbiol (2009) 0.81

Safety and pharmacokinetics of the anti-orthopoxvirus compound ST-246 following a single daily oral dose for 14 days in human volunteers. Antimicrob Agents Chemother (2012) 0.81

In vitro inhibition of monkeypox virus production and spread by Interferon-β. Virol J (2012) 0.81

Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med (1978) 14.65

Tularemia as a biological weapon: medical and public health management. JAMA (2001) 13.23

The outbreak of West Nile virus infection in the New York City area in 1999. N Engl J Med (2001) 11.48

Botulinum toxin as a biological weapon: medical and public health management. JAMA (2001) 9.18

Susceptibility of anaerobes to cefoxitin and other cephalosporins. Antimicrob Agents Chemother (1975) 8.86

Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA (2000) 8.45

Anaerobic infections. 1. N Engl J Med (1974) 8.02

Clindamycin-associated colitis due to a toxin-producing species of Clostridium in hamsters. J Infect Dis (1977) 7.68

Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA (1999) 7.06

Controlled trial of three different antismoking interventions in general practice. Br Med J (Clin Res Ed) (1984) 6.25

Quinolone-resistant Campylobacter jejuni infections in Minnesota, 1992-1998. Investigation Team. N Engl J Med (1999) 6.20

Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis. Gastroenterology (1978) 5.91

A plaque reduction test for dengue virus neutralizing antibodies. J Immunol (1967) 5.78

Comparison of two toxins produced by Clostridium difficile. Infect Immun (1981) 5.16

Epidemiology and clonality of community-acquired methicillin-resistant Staphylococcus aureus in Minnesota, 1996-1998. Clin Infect Dis (2001) 5.07

Glanders in a military research microbiologist. N Engl J Med (2001) 4.77

Clinical recognition and management of patients exposed to biological warfare agents. JAMA (1997) 4.67

Practice guidelines for the management of infectious diarrhea. Clin Infect Dis (2001) 4.49

Clostridium difficile colitis: an efficient clinical approach to diagnosis. Ann Intern Med (1995) 4.42

Cytotoxicity assay in antibiotic-associated colitis. J Infect Dis (1979) 4.39

A national outbreak of Salmonella enteritidis infections from ice cream. The Investigation Team. N Engl J Med (1996) 4.14

The psychiatric status of patients with the chronic fatigue syndrome. Br J Psychiatry (1990) 4.10

Isolation rates and toxigenic potential of Clostridium difficile isolates from various patient populations. Gastroenterology (1981) 4.04

Clindamycin-induced enterocolitis in hamsters as a model of pseudomembranous colitis in patients. Infect Immun (1978) 3.93

ELISA for the detection of antibodies to Ebola viruses. J Infect Dis (1999) 3.92

Weapons of mass destruction events with contaminated casualties: effective planning for health care facilities. JAMA (2000) 3.92

Experimental intra-abdominal abscesses in rats: development of an experimental model. Infect Immun (1974) 3.91

Clinical and laboratory observations in Clostridium difficile colitis. Am J Clin Nutr (1980) 3.89

Infectious disease surveillance: a crumbling foundation. Science (1994) 3.89

Quantitative bacteriology of the vaginal flora. J Infect Dis (1977) 3.81

A point-source outbreak of campylobacteriosis associated with consumption of raw milk. J Infect Dis (1985) 3.81

Principles of appropriate antibiotic use for acute pharyngitis in adults: background. Ann Intern Med (2001) 3.75

Management of anaerobic infections. Ann Intern Med (1975) 3.62

The capsular polysaccharide of Bacteroides fragilis as a virulence factor: comparison of the pathogenic potential of encapsulated and unencapsulated strains. J Infect Dis (1977) 3.62

Death due to bioterrorism-related inhalational anthrax: report of 2 patients. JAMA (2001) 3.55

Pathogenesis of experimental Ebola virus infection in guinea pigs. J Infect Dis (1999) 3.47

Ebola virus can be effectively neutralized by antibody produced in natural human infection. J Virol (1999) 3.44

Informed choice in genetic screening for thalassaemia during pregnancy: audit from a national confidential inquiry. BMJ (2000) 3.38

Rapid diagnosis of anaerobic infections by direct gas-liquid chromatography of clinical speciments. J Clin Invest (1976) 3.34

Anaerobic pleuropulmonary infections. Medicine (Baltimore) (1972) 3.30

Drug-resistant Salmonella from animals fed antimicrobials. N Engl J Med (1984) 3.26

Microbial synergy in experimental intra-abdominal abscess. Infect Immun (1976) 3.21

Prescription drug use and self-prescription among resident physicians. JAMA (1998) 3.20

Anaerobic infections (second of three parts). N Engl J Med (1974) 3.18

Viral burden and HIV disease. Nature (1993) 3.18

Principles of appropriate antibiotic use for acute rhinosinusitis in adults: background. Ann Intern Med (2001) 3.15

Colitis induced by Clostridium difficile. Rev Infect Dis (1980) 3.15

Anaerobic infections (third of three parts). N Engl J Med (1974) 3.13

Enzyme immunoassays for detection of Clostridium difficile toxins A and B in fecal specimens. J Infect Dis (1984) 3.07

Flaviviridae. Intervirology (1985) 3.06

An investigation of the cause of the eosinophilia-myalgia syndrome associated with tryptophan use. N Engl J Med (1990) 3.05

Treatment of anaerobic infections with lincomycin and clindamycin. N Engl J Med (1972) 3.05

Intra-aneurysmal thrombosis as a possible cause of delayed aneurysm rupture after flow-diversion treatment. AJNR Am J Neuroradiol (2010) 3.03

Antibiotic-associated pseudomembranous colitis. Rev Infect Dis (1980) 3.02

An outbreak of foodborne giardiasis. N Engl J Med (1981) 2.98

Clinical findings of West Nile virus infection in hospitalized patients, New York and New Jersey, 2000. Emerg Infect Dis (2001) 2.97

Oral vancomycin for antibiotic-associated pseudomembranous colitis. Lancet (1978) 2.87

Cultures for Clostridium difficile in stools containing a cytotoxin neutralized by Clostridium sordellii antitoxin. J Clin Microbiol (1979) 2.86

Cyclosporiasis and raspberries--lessons for the future. N Engl J Med (1997) 2.86

Pseudomembranous enterocolitis (antibiotic-related colitis). Adv Intern Med (1977) 2.73